Latest News - Avidity Biosciences
Effect of Long-Term Treatment of AOC 1001 in Adults with Myotonic Dystrophy Type 1: from MARINA® to MARINA-OLE™ AOC 1001-Mediated Reduction of DMPK Leads to Increase in Functional MBNL Levels, Improving Muscle Function in Patients with DM1
Avidity Biosciences Announces New Precision Cardiology …
6 days ago · Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...
Avidity Biosciences Announces New Precision Cardiology …
6 days ago · News provided by Avidity Biosciences, Inc. Nov 12, 2024, 07:00 ET. Share this article. Share to X. Share this article. Share to X. Avidity expands ...
Avidity Biosciences Reports Third Quarter 2024 Financial Results …
Nov 7, 2024 · News provided by Avidity Biosciences, Inc. Nov 07, 2024, 16:05 ET. Share this article. Share to X. Share this article. Share to X. Enrollment in global Phase 3 HARBOR™ study for del-desiran in ...
Avidity Biosciences Extends 416% Run With New Cardiovascular …
5 days ago · Avidity Biosciences stock had soared more than 416% this year, as of Tuesday's close. Shares have a perfect IBD Digital Relative Strength Rating of 99. This puts them in the top 1% of all stocks ...
Avidity Biosciences Reports Third Quarter 2024 Financial Results …
Nov 7, 2024 · Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported ...
Avidity Biosciences Receives FDA Breakthrough Therapy …
SAN DIEGO, May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences unveils new cardiology development …
4 days ago · Avidity Biosciences Inc. has announced two new precision cardiology development candidates targeting rare genetic cardiomyopathies. AOC-1086 targets phospholamban (PLN) cardiomyopathy and AOC-1072 targets protein kinase AMP-activated noncatalytic subunit γ2 (PRKAG2) syndrome.
How Avidity Biosciences Just Dropped The Hammer On Sarepta …
Aug 9, 2024 · Avidity Biosciences unveiled promising results for its Duchenne muscular dystrophy treatment on Friday. The top-notch biotech stock catapulted, while shares of rival Sarepta Therapeutics ( SRPT...
Avidity Biosciences Announces Expansion of Cardiovascular …
Nov 28, 2023 · Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced a...